{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:53:07Z","timestamp":1777423987645,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although targeting of the cholesterol pathway by statins prevents breast cancer development in mouse models, efficacy is not absolute. Therefore, the goal of this study is to investigate if the upregulation in the cholesterol biosynthesis pathway genes associates with response to statin chemoprevention and may potentially be used as response biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Expression of cholesterol biosynthesis pathway genes was initially derived from the RNA sequencing of MCF10A cell line- based breast cancer progression model system and subsequently validated by quantitative PCR assay. Response to fluvastatin was assessed in vitro using the MCF10A cell line model system, including a statin resistant cell line that was generated (MCF10.AT1-R), and measured using colony forming assays. In vivo efficacy of statin for chemoprevention was assessed in the SV40C3 TAg mouse model. Mammary tumors were identified by histologic analysis of the mammary glands. Mammary glands without histologic evidence of high-grade lesions (in situ and\/or invasive carcinoma) were considered responsive to statin treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found more than 70% of a published multi-gene fluvastatin resistance signature to be significantly upregulated during breast cancer progression and inversely correlated with statin inhibition of cellular growth and proliferation. This inherent statin resistance gene signature was also largely shared with the signature of acquired resistance to fluvastatin in MCF10.AT1-R cell line model of acquired statin resistance. These inherent resistance genes and genes exclusive to acquired statin resistance map to steroid-, and terpenoid backbone- biosynthesis pathway. We found upregulation of\u2009~\u200980% of cholesterol biosynthesis pathway genes in the tumor bearing mammary glands of SV40 C3TAg transgenic mouse model of TNBC, suggesting the involvement of cholesterol biosynthesis pathway in resistance to statin chemoprevention in vivo. A panel of 13-genes from the pathway significantly associated with response to statin treatment, as did the expression level of HMGCR alone in a mouse model of breast cancer suggesting their utility to predict the efficacy of statin chemoprevention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>High basal level, or restorative upregulation, in the cholesterol biosynthesis pathway genes appear to be strongly associated with resistance to statin chemoprevention for breast cancer and may serve as a biomarker to tailor statin\u00a0treatment to individuals who are most likely to benefit.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-022-09353-2","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T04:38:50Z","timestamp":1647491930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Anjana","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Embury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenlin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bedrosian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"issue":"3","key":"9353_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s10549-011-1858-7","volume":"131","author":"MJ Higgins","year":"2012","unstructured":"Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, et al. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat. 2012;131(3):915\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"9353_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-013-2473-6","volume":"138","author":"O Bjarnadottir","year":"2013","unstructured":"Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, Uhlen M, Johannesson H, Rose C, Grabau D, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138(2):499\u2013508.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"9353_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-013-2739-z","volume":"142","author":"S Vinayak","year":"2013","unstructured":"Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, et al. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat. 2013;142(2):389\u201398.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9353_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-016-3849-1","volume":"158","author":"BK Arun","year":"2016","unstructured":"Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, et al. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016;158(1):67\u201377.","journal-title":"Breast Cancer Res Treat"},{"key":"9353_CR5","doi-asserted-by":"crossref","unstructured":"Bhardwaj A, Embury MD, Rojo RD, Albarracin C, Bedrosian I: Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Res Treat\u00a02021.","DOI":"10.1007\/s10549-021-06229-0"},{"issue":"1","key":"9353_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13058-018-1074-z","volume":"20","author":"A Bhardwaj","year":"2018","unstructured":"Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018;20(1):150.","journal-title":"Breast Cancer Res"},{"issue":"17","key":"9353_CR7","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1158\/0008-5472.CAN-05-4061","volume":"66","author":"MJ Campbell","year":"2006","unstructured":"Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66(17):8707\u201314.","journal-title":"Cancer Res"},{"issue":"34","key":"9353_CR8","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.0910258107","volume":"107","author":"JW Clendening","year":"2010","unstructured":"Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010;107(34):15051\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"9353_CR9","doi-asserted-by":"publisher","first-page":"59640","DOI":"10.18632\/oncotarget.10746","volume":"7","author":"S Kimbung","year":"2016","unstructured":"Kimbung S, Lettiero B, Feldt M, Bosch A, Borgquist S. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer. Oncotarget. 2016;7(37):59640\u201351.","journal-title":"Oncotarget"},{"issue":"2","key":"9353_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77\u2013106.","journal-title":"Genes Dis"},{"issue":"1","key":"9353_CR11","first-page":"313","volume":"148","author":"PJ Dawson","year":"1996","unstructured":"Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol. 1996;148(1):313\u20139.","journal-title":"Am J Pathol"},{"issue":"14","key":"9353_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/jnci\/92.14.1185a","volume":"92","author":"FR Miller","year":"2000","unstructured":"Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000;92(14):1185-1186.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"9353_CR13","doi-asserted-by":"publisher","first-page":"e97076","DOI":"10.1371\/journal.pone.0097076","volume":"9","author":"A Bhardwaj","year":"2014","unstructured":"Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PloS one. 2014;9(5):e97076.","journal-title":"PloS one"},{"issue":"12","key":"9353_CR14","doi-asserted-by":"publisher","first-page":"19645","DOI":"10.18632\/oncotarget.14902","volume":"8","author":"A Bhardwaj","year":"2017","unstructured":"Bhardwaj A, Singh H, Rajapakshe K, Tachibana K, Ganesan N, Pan Y, Gunaratne PH, Coarfa C, Bedrosian I. Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. Oncotarget. 2017;8(12):19645\u201360.","journal-title":"Oncotarget"},{"key":"9353_CR15","doi-asserted-by":"crossref","unstructured":"Ju Z, Bhardwaj A, Embury MD, Singh H, Gunaratne PH, Bedrosian I, Wang J: Integrative Analyses of Multilevel Omics Reveal Preneoplastic Breast to Possess a Molecular Landscape That is Globally Shared with Invasive Basal-Like Breast Cancer (Running Title: Molecular Landscape of Basal-Like Breast Cancer Progression). Cancers (Basel) 2020, 12(3).","DOI":"10.3390\/cancers12030722"},{"issue":"3","key":"9353_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nbt0308-303","volume":"26","author":"M Ringner","year":"2008","unstructured":"Ringner M. What is principal component analysis? Nat Biotechnol. 2008;26(3):303\u20134.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"9353_CR17","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"9353_CR18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc: Ser B (Methodol). 1995;57(1):289\u2013300.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"issue":"1","key":"9353_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13058-019-1124-1","volume":"21","author":"L Garcia-Estevez","year":"2019","unstructured":"Garcia-Estevez L, Moreno-Bueno G. Updating the role of obesity and cholesterol in breast cancer. Breast Cancer Res. 2019;21(1):35.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"9353_CR20","first-page":"2168","volume":"49","author":"MR Wrensch","year":"1989","unstructured":"Wrensch MR, Petrakis NL, Gruenke LD, Miike R, Ernster VL, King EB, Hauck WW, Craig JC, Goodson WH 3rd. Breast fluid cholesterol and cholesterol beta-epoxide concentrations in women with benign breast disease. Cancer Res. 1989;49(8):2168\u201374.","journal-title":"Cancer Res"},{"issue":"1","key":"9353_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41467-017-00910-z","volume":"8","author":"AE Baek","year":"2017","unstructured":"Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, Pillai RV, McDowell HB, Thompson JW, Dubois LG, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8(1):864.","journal-title":"Nat Commun"},{"issue":"2","key":"9353_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-6654-9","volume":"94","author":"M Bahl","year":"2005","unstructured":"Bahl M, Ennis M, Tannock IF, Hux JE, Pritchard KI, Koo J, Goodwin PJ. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat. 2005;94(2):135\u201344.","journal-title":"Breast Cancer Res Treat"},{"key":"9353_CR23","doi-asserted-by":"publisher","first-page":"10044","DOI":"10.1038\/ncomms10044","volume":"6","author":"VT Nguyen","year":"2015","unstructured":"Nguyen VT, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, Darbre P, Castellano L, Gyorffy B, Woodley L, et al. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nat Commun. 2015;6:10044.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"9353_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","volume":"148","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148(1\u20132):244\u201358.","journal-title":"Cell"},{"issue":"3","key":"9353_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/carcin\/24.3.453","volume":"24","author":"MA Shibata","year":"2003","unstructured":"Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003;24(3):453\u20139.","journal-title":"Carcinogenesis"},{"issue":"1","key":"9353_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-012-2154-x","volume":"135","author":"K Undela","year":"2012","unstructured":"Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135(1):261\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9353_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-009-0507-x","volume":"119","author":"ER Garwood","year":"2010","unstructured":"Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119(1):137\u201344.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09353-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T12:22:49Z","timestamp":1726834969000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9353"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09353-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal work related experimental protocols in this study were approved by the UT MD Anderson Cancer Center Institutional Animal care and Use Committee (IACUC). The study was carried out in compliance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. This article does not contain any studies with human participants. All the experiments were conducted in accordance with relevant guidelines and regulations including Institutional guidelines of UT MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}